The effects of various single oral doses of micronized benzbromarone on serum and urinary uric acid and urinary oxypurines were studied in 5 healthy volunteers and in 5 patients with gout. There was an effective, unequivocal, and dose‐related reduction in serum uric acid levels in both groups. The simultaneous increased excretion of urinary uric acid but not of oxypurines suggests the mechanism of effect is uricosuria. The prolonged duration of action up to 48 hours after dosing is advantageous as the drug need be taken only once a day. The data presented favor a protracted trial of benzbromarone in patients with gout and hyperuricemia.
No takes yet. Share an insight, caveat, or question.
Jain et al. (1974) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: